Benjamin Alan Pinsky, MD, PHD
Anatomic Pathology & Clinical Pathology · Stanford
- Medicare standing
- 1 flag on the record
- Listed below.
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
On the public record
- Medicare does not list them as allowed to order and refer
Offices
1 location
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Pinsky’s office at (650) 723-4000 to ask if they take your plan before you enroll.
California Medical Board record
Licence A105139 · Current
Licensed to practise in California · since 2008 · expires 2028-07-31 · University of Washington School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Money from drug and device companies
$815 in 2025
| 2025 | 3 | 4 | $588 | $815 |
| 2024 | 1 | 1 | $725 | $725 |
| 2023 | 1 | 1 | None | $70 |
| 2022 | 1 | 1 | None | $47 |
| 2021 | 3 | 3 | $3,200 | $3,225 |
| 2019 | 1 | 4 | $8,000 | $8,220 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Cepheid | None | $588 | 1 payment
|
| Hologic Sales and Service | Aptima | $135 | 2 payments
|
| Roche Molecular Systems | Cobas® Ebv | $91 | 1 payment
|
See all 4 published payments
| Hologic Sales and Service | Meals · 2025-11-13 | Aptima | $41 |
| Hologic Sales and Service | Meals · 2025-07-29 | Aptima | $95 |
| Cepheid | Consulting · 2025-07-10 | None | $588 |
| Roche Molecular Systems | Meals · 2025-04-13 | Cobas® Ebv | $91 |
See earlier years (2024, 2023, 2022, 2021, 2019)
2024: $725
| Cepheid | None | $725 | 1 payment
|
2023: $70
| Hologic Sales and Service | Aptima | $70 | 1 payment
|
2022: $47
| Gen-Probe | Aptima | $47 | 1 payment
|
2021: $3,225
| GenMark Diagnostics | Eplex | $2,000 | 1 payment
|
| Beckman Coulter | None | $1,200 | 1 payment
|
| Gen-Probe | Aptima | $25 | 1 payment
|
2019: $8,220
| GenMark Diagnostics | None | $8,220 | 3 payments
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Agilent Technologies, Inc. · Evaluation of Agilent Sars-Cov-2 Qrt-Pcr Assay · 2020 | Their institution | $163,092 |
| Abbott Laboratories · Alinity I Toxo Igm Design Validation Protocol · 2023 | Their institution | $111,247 |
| Abbott Laboratories · Alinity I Rubella Igg Design Validation Protocol · 2023 | Their institution | $91,446 |
| Abbott Laboratories · Architect Toxo Igg Design Validation Protocol · 2020 | Their institution | $76,761 |
| Gen-Probe, Inc. · Evaluation of the Aptima Cmv Quant Assay in Plasma and Non-Plasma Samples · 2023 | Their institution | $75,000 |
| Abbott Laboratories · 09dy-02-18g03-01 Architect Cmv Igg Design Validation · 2021 | Their institution | $64,457 |
| Abbott Laboratories · Architect Toxo Igg Design Validation Protocol · 2019 | Their institution | $43,400 |
| Gen-Probe, Inc. · Evaluation of the Aptima Cmv Quant Assay in Plasma and Non-Plasma Samples · 2022 | Their institution | $25,000 |
| Abbott Laboratories · Alinity I Toxo Igm Design Validation Protocol # 09dy-02-22g01-01 · 2024 | Their institution | $7,406 |
| Abbott Laboratories · Alinity I Havab-G II Design Validation · 2021 | Their institution | $2,467 |
Professional record
- NPI
- 1124216643
- Licence
- CA 390200000X, CA A105139California A105139: Current · expires 2028-07-31
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207ZP0102X (207ZP0102X); Federal specialty code 207ZC0006X (207ZC0006X); Federal specialty code 207ZP0105X (207ZP0105X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2007-10-10
- NPI last updated
- 2024-03-21
- NPI record certified
- 2024-03-21
This is when the NPI record was last certified, not a medical board exam.